Other Data

financial-banner

Other Data

bse
nse

Conference Call Transcripts

pdf-icon

Q1 FY2017 Conference Call Transcript

pdf-icon

Postal Ballot Results 13.3.2017

pdf-icon

Q4 and Full Year FY2016 Conference Call Transcript

pdf-icon

Concall to discuss the Sale of Certain Products in SpecChem Division

pdf-icon

Vivimed_Q1_FY2015
Conference_Call_Transcript

pdf-icon

Vivimed_Q2_FY2015
Conference_Call_Transcript

pdf-icon

Vivimed_Q3_FY2015
Conference_Call_Transcript

pdf-icon

Q4 and Full Year FY2014 Conference Call Transcript

pdf-icon

Q3 FY2014 Conference Call Transcript

pdf-icon

Q2 FY2014 Conference Call Transcript

pdf-icon

Q1 FY2014 Conference Call Transcript

pdf-icon

Actavis Acquisition Call Transcript

pdf-icon

Q4 FY2013 Earnings Call Transcript

pdf-icon

Q4 and Full Year FY2013 Conference Call Invite

pdf-icon

Q3 FY2013 Earnings Call Transcript

pdf-icon

Q2 FY2013 Earnings Call Transcript

pdf-icon

Q1 FY2013 Earnings Call Transcript


Corporate Policies

pdf-icon

Corporate Governance

pdf-icon

Code of Conduct

pdf-icon

Code of Conduct for Directors and Management

pdf-icon

Terms and Conditions of Appointment of Independent Directors

pdf-icon

Criteria of Making Payments to Non-Executive Directors

pdf-icon

Key Managerial Person

pdf-icon

Familarisation Programme for Independent Directors

pdf-icon

Policy on Determination of Materiality

pdf-icon

Policy of Related Party

pdf-icon

Insider Trading Policy (UPSI)

pdf-icon

Whistle Blowers Policy

pdf-icon

Policy on Material Subsidiary

pdf-icon

Archival Policy

pdf-icon

Risk Policy

pdf-icon

CSR Policy


Investor Presentation

pdf-icon

Investor Presentation May 2015


Postal Ballot Notice

Postal-Ballot-Notice

Postal Ballot Notice


Press Releases

pdf-icon

Announces Sale of Certain Products of its Subsidiary (Jul-16)

pdf-icon

CCI Approval (Dec-15)

pdf-icon

Sale of Certain Products in SpecChem Division (Sep-15)

pdf-icon

Satisfactory Outcome of USFDA Inspection (Sep-15)

pdf-icon

Q1 FY2014 Earnings Press Release

pdf-icon

Acquires a US FDA approved formulation manufacturing facility

pdf-icon

Clarification

pdf-icon

Receives the PIC/S GMP approval for one of its pharmaceuticals manufacturing facilities in Hyderabad

pdf-icon

Share Price Clarification

pdf-icon

Clarification on allotment of Equity Shares

pdf-icon

Allotment of Equity Shares

pdf-icon

08-Mar-2013: Care Ratings


Research Coverage

pdf-icon

Reliance – Feb 2013

pdf-icon

Sumedha – Dec 2012

pdf-icon

Fullerton – Nov 2012

pdf-icon

MSFL – Aug 2012

pdf-icon

Sumedha – Jun 2012

pdf-icon

Reliance – Jun 2012

pdf-icon

Reliance – Apr 2012


Research Reports

pdf-icon

Anand Rathi April 2015


Scheme of Amalgamation

pdf-icon

Vivimed Letter to BSE (Sept 2017)

pdf-icon

Vivimed Letter to NSE (Sept 2017)

pdf-icon

Observation Letter Regarding Scheme of Amalgamation – BSE (Apr 2016)

pdf-icon

Observation Letter Regarding Scheme of Amalgamation – NSE (Apr 2016)

pdf-icon

Scheme of Amalgamation – BSE (Aug 2014)

pdf-icon

Scheme of Amalgamation – NSE (Aug 2014)

pdf-icon

Creative Health Memorandum and Article of Association

pdf-icon

Klar Sehen Memorandum and Article of Association

pdf-icon

Octtantis Memorandum and Article of Association

pdf-icon

Vivimed Memorandum and Article of Association

pdf-icon

Alathur Change of Name (Aug 2013)

pdf-icon

Alathur FY2012 Financial Results

pdf-icon

Alathur FY2014 Financial Results

pdf-icon

Creative Health FY2014 Annual Report

pdf-icon

Creative Health FY2013 Annual Report

pdf-icon

Creative Health FY2012 Annual Report

pdf-icon

Klar Shen FY2014 Annual Report

pdf-icon

Klar Sehen FY2014 Financial Results

pdf-icon

Klar Shen FY2013 Annual Report

pdf-icon

Klar Shen FY2012 Annual Report

pdf-icon

Octtantis FY2014 Financial Results

pdf-icon

Octtantis FY2013 Financial Results

pdf-icon

Octtantis FY2012 Financial Results